Icatibant Zentiva

Icatibant acetate, the active ingredient in Icatibant Zentiva, is a bradykinin B2 receptor antagonist presented as a sterile solution for injection for subcutaneous use. It is indicated for the treatment of acute attacks of hereditary angioedema in adult patients, providing rapid reduction of swelling and associated discomfort.

GNH USA supplies Icatibant Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, delivering consistent quality and regulatory‑approved product for patients with hereditary angioedema. The product complies with EU marketing authorisation and is distributed under strict quality standards.

Icatibant Zentiva is used to treat hereditary angioedema, a bradykinin‑mediated swelling disorder.

Hereditary angioedema type I: Provides rapid reduction of swelling, relieves pain, and shortens attack duration during acute episodes. Hereditary angioedema type II: Provides rapid reduction of swelling, relieves pain, and shortens attack duration during acute episodes. Hereditary angioedema with normal C1‑INH (HAE‑nC1INH): Offers symptom control and swelling reduction during acute attacks, though use may be off‑label in certain jurisdictions.

Icatibant Zentiva may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Injection site pain - Erythema at the injection site - Local swelling - Nausea - Headache - Dizziness

Serious or Rare Side Effects: - Hypersensitivity reactions including anaphylaxis - Severe hypotension - Airway angioedema - Thrombocytopenia - Injection‑site necrosis - Severe rash or Stevens‑Johnson syndrome

When prescribing Icatibant Zentiva, clinicians should consider several safety precautions.

Pregnancy: Use only if clearly needed; safety data are limited. Breastfeeding: Caution; it is unknown whether the drug is excreted in human milk. Renal impairment: No dose adjustment is required, but monitor for accumulation. Concomitant ACE inhibitors or ARBs: May increase risk of bradykinin‑mediated angioedema; observe patients closely. Hypersensitivity: Discontinue immediately if a severe allergic reaction occurs. Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Icatibant Zentiva can interact with other medicines that influence bradykinin pathways or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: May potentiate bradykinin‑mediated angioedema. - Angiotensin receptor blockers (ARBs): Similar risk of enhanced angioedema. - Other bradykinin B2 antagonists: No additive benefit; avoid co‑administration. - Simultaneous use of prophylactic C1‑INH concentrate: May interfere with clinical assessment of efficacy.

Moderate Interactions (Monitor Closely): - NSAIDs: May increase risk of angioedema. - Estrogen‑containing contraceptives: Can exacerbate hereditary angioedema attacks. - Diuretics: May affect fluid balance during acute episodes.